Cargando…

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Cetuximab is a standard-of-care treatment for RAS wild-type metastatic colorectal cancer (mCRC) but not for those harbor a KRAS mutation since MAPK pathway is constitutively activated. Nevertheless, cetuximab also exerts its effect by its immunomodulatory activity despite the presence of RAS mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385198/
https://www.ncbi.nlm.nih.gov/pubmed/30796344
http://dx.doi.org/10.1038/s41598-019-39291-2

Ejemplares similares